TenNor Therapeutics

company

About

TenNor Therapeutics specializes in research and development of new drugs for the treatment of digestive diseases

  • 1 - 10

Details

Last Funding Type
Series D
Last Funding Money Raised
¥264M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for the treatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
¥264M $25M
TenNor Therapeutics has raised a total of ¥264M $25M in funding over 2 rounds. Their latest funding was raised on Mar 30, 2022 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 30, 2022 Series D ¥264M 1 Detail
Sep 19, 2016 Series B $25M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
TenNor Therapeutics is funded by 2 investors. Zhongnuo Venture Capital and Relativity Healthcare Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Zhongnuo Venture Capital Series D
Relativity Healthcare Partners Series B